Cellular-based Immunotherapies for Patients with Glioblastoma Multiforme

Overview

Journal Clin Dev Immunol

Specialty Allergy & Immunology

Date 2012 Apr 5

PMID 22474481

Citations 14

Authors

Xun Xu

Florian Stockhammer

Michael Schmitt

Affiliations

Soon will be listed here.

Abstract

Treatment of patients with glioblastoma multiforme (GBM) remains to be a challenge with a median survival of 14.6 months following diagnosis. Standard treatment options include surgery, radiation therapy, and systemic chemotherapy with temozolomide. Despite the fact that the brain constitutes an immunoprivileged site, recent observations after immunotherapies with lysate from autologous tumor cells pulsed on dendritic cells (DCs), peptides, protein, messenger RNA, and cytokines suggest an immunological and even clinical response from immunotherapies. Given this plethora of immunomodulatory therapies, this paper gives a structure overview of the state-of-the art in the field. Particular emphasis was also put on immunogenic antigens as potential targets for a more specific stimulation of the immune system against GBM.

Citing Articles

Diffuse intrinsic pontine glioma (DIPG): A review of current and emerging treatment strategies.

Weisbrod L, Thiraviyam A, Vengoji R, Shonka N, Jain M, Ho W Cancer Lett. 2024; 590:216876.

PMID: 38609002 PMC: 11231989. DOI: 10.1016/j.canlet.2024.216876.

Potential Molecular Mechanism of TNF Superfamily-Related Genes in Glioblastoma Multiforme Based on Transcriptome and Epigenome.

Xie H, Yuan C, Li J, Li Z, Lu W Front Neurol. 2021; 12:576382.

PMID: 33643183 PMC: 7905170. DOI: 10.3389/fneur.2021.576382.

Probing the Bi-directional Interaction Between Microglia and Gliomas in a Tumor Microenvironment on a Microdevice.

Gu R, Zhang X, Zhang G, Tao T, Yu H, Liu L Neurochem Res. 2017; 42(5):1478-1487.

PMID: 28236212 DOI: 10.1007/s11064-017-2204-1.

Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis.

Artene S, Turcu-Stiolica A, Hartley R, Ciurea M, Daianu O, Brindusa C Onco Targets Ther. 2016; 9:6669-6677.

PMID: 27877052 PMC: 5108618. DOI: 10.2147/OTT.S112842.

The Effect of Vector Silencing during Picornavirus Vaccination against Experimental Melanoma and Glioma.

Malo C, Renner D, Huseby Kelcher A, Jin F, Hansen M, Pavelko K PLoS One. 2016; 11(8):e0162064.

PMID: 27560502 PMC: 4999064. DOI: 10.1371/journal.pone.0162064.

References

Hau P, Koch D, Hundsberger T, MARG E, Bauer B, Rudolph R . Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology. 2007; 68(9):688-90. DOI: 10.1212/01.wnl.0000255937.27012.ee. View

Vredenburgh J, Desjardins A, Herndon 2nd J, Dowell J, Reardon D, Quinn J . Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13(4):1253-9. DOI: 10.1158/1078-0432.CCR-06-2309. View

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

Bao L, Dunham K, Lucas K . MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing. Cancer Immunol Immunother. 2011; 60(9):1299-307. PMC: 11029270. DOI: 10.1007/s00262-011-1037-z. View

Hayes R, Koslow M, Hiesiger E, Hymes K, Hochster H, Moore E . Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer. 1995; 76(5):840-52. DOI: 10.1002/1097-0142(19950901)76:5<840::aid-cncr2820760519>3.0.co;2-r. View

Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28):4733-40. DOI: 10.1200/JCO.2008.19.8721. View

Perry J, Rizek P, Cashman R, Morrison M, Morrison T . Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach. Cancer. 2008; 113(8):2152-7. DOI: 10.1002/cncr.23813. View

Barba D, Saris S, Holder C, Rosenberg S, Oldfield E . Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg. 1989; 70(2):175-82. DOI: 10.3171/jns.1989.70.2.0175. View

Yu J, Liu G, Ying H, Yong W, Black K, Wheeler C . Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004; 64(14):4973-9. DOI: 10.1158/0008-5472.CAN-03-3505. View

10.

Ardon H, de Vleeschouwer S, Van Calenbergh F, Claes L, Kramm C, Rutkowski S . Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer. 2009; 54(4):519-25. DOI: 10.1002/pbc.22319. View

11.

Vredenburgh J, Desjardins A, Herndon 2nd J, Marcello J, Reardon D, Quinn J . Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25(30):4722-9. DOI: 10.1200/JCO.2007.12.2440. View

12.

Stummer W, Pichlmeier U, Meinel T, Wiestler O, Zanella F, Reulen H . Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006; 7(5):392-401. DOI: 10.1016/S1470-2045(06)70665-9. View

13.

Wheeler C, Black K, Liu G, Ying H, Yu J, Zhang W . Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J Immunol. 2003; 171(9):4927-33. DOI: 10.4049/jimmunol.171.9.4927. View

14.

Lewis-Tuffin L, Rodriguez F, Giannini C, Scheithauer B, Necela B, Sarkaria J . Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS One. 2010; 5(10):e13665. PMC: 2965143. DOI: 10.1371/journal.pone.0013665. View

15.

Ferletta M, Uhrbom L, Olofsson T, Ponten F, Westermark B . Sox10 has a broad expression pattern in gliomas and enhances platelet-derived growth factor-B--induced gliomagenesis. Mol Cancer Res. 2007; 5(9):891-7. DOI: 10.1158/1541-7786.MCR-07-0113. View

16.

Kogiku M, Ohsawa I, Matsumoto K, Sugisaki Y, Takahashi H, Teramoto A . Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor. J Clin Neurosci. 2008; 15(11):1198-203. DOI: 10.1016/j.jocn.2007.11.012. View

17.

Thara E, Dorff T, Pinski J, Quinn D . Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas. 2011; 69(4):296-303. DOI: 10.1016/j.maturitas.2011.04.012. View

18.

Okada H, Lieberman F, Walter K, Lunsford L, Kondziolka D, Bejjani G . Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med. 2007; 5:67. PMC: 2254376. DOI: 10.1186/1479-5876-5-67. View

19.

Wehner R, Lobel B, Bornhauser M, Schakel K, Cartellieri M, Bachmann M . Reciprocal activating interaction between 6-sulfo LacNAc+ dendritic cells and NK cells. Int J Cancer. 2008; 124(2):358-66. DOI: 10.1002/ijc.23962. View

20.

Villavicencio A, Burneikiene S, Romanelli P, Fariselli L, McNeely L, Lipani J . Survival following stereotactic radiosurgery for newly diagnosed and recurrent glioblastoma multiforme: a multicenter experience. Neurosurg Rev. 2009; 32(4):417-24. DOI: 10.1007/s10143-009-0212-6. View